Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Kyverna Therapeutics, Inc. ( (KYTX) ).
Kyverna Therapeutics appointed Gregory (Greg) Martini as chief financial officer, effective May 18, 2026, succeeding Marc Grasso, M.D., who will remain as a strategic advisor through at least August 1, 2026 to support a seamless transition. Martini, a veteran biopharma finance executive most recently serving as senior vice president and CFO at Ironwood Pharmaceuticals, will lead Kyverna’s financial strategy, capital allocation, and investor relations as the company advances miv-cel toward a potential first approval in stiff person syndrome and prepares to transition into a commercial-stage organization.
Under the terms of an offer letter signed on May 8, 2026, Martini will receive a base salary of $525,000, eligibility for a 40% annual performance bonus, a $300,000 sign-on bonus subject to clawback on early voluntary departure, and an inducement stock option for 325,000 shares vesting over four years, alongside defined severance and change-in-control protections. Grasso’s departure as CFO, which the company said did not stem from any disagreement over operations or financial reporting, is accompanied by a letter agreement providing him continued salary, equity vesting, and COBRA reimbursement for 12 months, underscoring Kyverna’s effort to maintain leadership continuity and financial discipline during a critical growth phase.
The most recent analyst rating on (KYTX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and substantial cash burn), partly offset by strong technical momentum (trading above major moving averages with positive MACD) and positive corporate updates (encouraging clinical data and strengthened commercial/board leadership). Valuation contributes limited support due to negative earnings and no dividend data.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, with a focus on its lead autologous CD19-targeting CAR T-cell candidate miv-cel (mivocabtagene autoleucel, KYV-101). The company is building a potentially first-in-class neuroimmunology franchise, targeting B-cell-driven autoimmune disorders such as stiff person syndrome, generalized myasthenia gravis, multiple sclerosis, and rheumatoid arthritis, while advancing a next-generation CAR T pipeline aimed at improving patient access and experience.
Average Trading Volume: 883,867
Technical Sentiment Signal: Strong Buy
Current Market Cap: $576.9M
For a thorough assessment of KYTX stock, go to TipRanks’ Stock Analysis page.